Multispecific antibody constructs

Multispecific antibodies with conditional activity are developed to enhance binding affinity and avidity under abnormal conditions, addressing the need for targeted therapeutic efficacy in tumor microenvironments.

JP2026123122AInactive Publication Date: 2026-07-29BIOATLA LLC
0 Cites 0 Cited by

Patent Information

Application Number
JP2026070729
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-06-14
Filing Date
2026-04-22
Publication Date
2026-07-29
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing multispecific antibodies do not effectively modulate activity based on physiological conditions, lacking conditional activity that is significantly enhanced under abnormal conditions while maintaining or improving activity levels compared to normal conditions.

Method used

Development of multispecific antibodies with conditional activity, designed to bind with greater affinity and/or avidity to specific antigens under abnormal conditions such as tumor microenvironments, utilizing IgG antibodies and scFv antibodies linked via a linker, with specific variable regions for enhanced binding properties.

Benefits of technology

The multispecific antibodies exhibit significantly higher activity ratios under abnormal conditions compared to normal conditions, facilitating targeted therapeutic applications, particularly in tumor treatment.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides a multispecific antibody having at least one conditional activity and a method for producing the same. [Solution] A multispecific antibody comprises at least one binding site for a cell-specific antigen and at least one binding site for a tumor-reactive lymphocyte antigen, and the multispecific antibody comprises an IgG antibody or fragment thereof that binds to a first antigen; and at least one scFv antibody that binds to a second antigen different from the first antigen and is ligated to the C-terminus of at least one light chain or heavy chain of the IgG antibody or fragment. This multispecific antibody reversibly binds to the cell-specific antigen and the tumor-reactive lymphocyte antigen or at least one of the first antigen and the second antigen with greater affinity under abnormal conditions than under normal physiological conditions. Conjugates of multispecific antibodies and methods for producing multispecific antibodies are also provided.
Need to check novelty before this filing date? Find Prior Art